Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide LAR and immunologic response in neuroendocrine tumors
2017-001613-83Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- May 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of octreotide in neuroendocrine tumour (NET), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: Change in T regulatory cells (T-Reg) from baseline to month 6 and Change in myeloid-derived suppressor cells (MDSC) from baseline to month 6. Started May 2021; status: completed.
02
Drugs
octreotide
03
Conditions
neuroendocrine tumour (NET)
Beyond the preview
Go deeper on 2017-001613-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001613-83.